Nitto Group Report 2016

24/44

23Nitto Group Report 2016Medical ServicesThe Nitto Group implements optimal intellectual property activities according to our business strategy in order to achieve the industrialization and market penetration of technologies, services and products which we have developed. For example, we are adopting a new strategy, which includes such things as protecting business models like Roll to Panel® (refer to page 20). Furthermore, the global application rate of the Nitto Group is more than 65%, which is relatively high (approximately 30% for the Japanese rate), and the globalization of our intellectual property activities continues to progress, in accordance with our business development. As recognition of such activities, the Nitto Group received a Thomson Reuters Top 100 Global Innovator award for the fth consecutive year. The award is given to the most innovative corporations and research institutes.05001,0001,5002,0002,5003,0003,5004,00020152014201220132005200620072008200920102011(Number of patent publications)*1: World Intellectual Property Organization *2: European Patent Ofce(Year of patent) publicationsWIPO*1EPO*2Taiwan　KoreaChinaUnited StatesJapan• Patent Publications of the Nitto Group (In Japan and major countries)Linking intellectual property rights allowing effective use of rights forcompetitive business advantageMarket-appropriateintellectual propertystrategiesBusiness growth (by business sector and area)Amalgamation of business and intellectual property Intellectual Property Activities Linking to Business ResultsInnovation for CustomersPushing forward in unison withother business units Mr. Masaki Nagao, Thomson Reuters’ Managing Director (left) with Mr. Hideo Takasaki, President of NittoFor ExampleProtecting Business with Intellectual PropertyFeatureMedical and sanitary materialsSurgical tapeFilm dressingTransdermal drug delivery patchesFor asthma treatmentFor local anesthesiaAnti-fibrosis Drug with Molecular Targeting DDS Technology PlatformNucleic Acid MedicinesEstablishment of Nitto BioPharma, Inc. , Devoted to Drug Discoveries in the USDrug delivery system (DDS) is a technology that steadily delivers drugs to an affected area. With the aim of industrializing the rst drug discovery within the Group, we are engaged in the development of therapeutic agents for intractable diseases long-awaited by a great many patients using our DDS technology.A drug for liver cirrhosis, which is at a pre-industrialization stage, is currently being tested for its safety and efcacy in patients, progressing steadily toward practical use.Nucleic acid medicines are pharmaceutical products produced from the structural components of DNA and RNA, called nucleic acid (oligonucleotide). Through direct action on genes and proteins, these medicines hold great promise for treating diseases such as cancer that were formerly difcult to treat. The Nitto Group develops and distributes NittoPhase® high-performance polymer beads for the synthesis of nucleic acid medicine (essentially carriers for solid-phase synthesis), while also providing manufacturing of a number of drugs and various related services. On January 11, 2016, we established a new company devoted to drug discoveries in the US. We are planning to relocate a development base to the north of San Diego where life science business is concentrated, further accelerating the industrialization of drug discoveries. Medical agentCarrierTargetingagentShip carryingmedical agentNavigatorsiRNAProposals for the Future!FineFine2015NittoPhase®

※このページを正しく表示するにはFlashPlayer10.2以上が必要です